Market Intelligence, Clinical Progress, and High-Purity Reagents for Cancer Metastasis and Epitranscriptomics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for YTHDF3 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | YTHDF3 Recombinant Protein (WT / YTH Domain) High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for SPR/FP assays. |
View YTHDF3 Products |
| Gene Delivery | YTHDF3 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and target engagement assays. |
View YTHDF3 Products |
| Benchmark Ab | Anti-YTHDF3 Recombinant Antibody High-affinity positive control for Western Blot, IP, and IHC validation. |
View YTHDF3 Products |
| Validator | YTHDF3 siRNA Set For target knockdown verification and functional validation. |
View YTHDF3 Products |
| Related Target A | YTHDF1 Homologous m6A reader; crucial for counter-screening and subfamily selectivity profiling. |
View YTHDF1 Products |
| Related Target B | YTHDF2 Homologous m6A reader associated with mRNA decay; required for off-target assessment. |
View YTHDF2 Products |
| Related Target C | METTL3 Upstream m6A methyltransferase (writer); key synergistic target in epitranscriptomics pathways. |
View METTL3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily selectivity screening (YTHDF1/2/3) | Homologue panel proteins strictly verified by mass spectrometry and sequence alignment. |
| RNA-binding pocket specificity confirmation | Specific YTH domain mutant proteins available as negative controls. |
| Lack of clinical-grade positive controls | Sequence-verified recombinant benchmark antibodies included. |
| Off-target phenotype interference | Validated siRNA pools included for gene knockdown verification. |
Live YTHDF3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the m6A reader YTHDF3 is rapidly emerging as a cornerstone of epitranscriptomics-driven oncology. Historically viewed as challenging due to high structural homology among YTH domain-containing proteins, the discovery of highly selective small-molecule inhibitors and PROTACs (proteolysis-targeting chimeras) has shifted the clinical paradigm. As first-generation epitranscriptomic therapies (such as METTL3 inhibitors) advance through early clinical phases, targeting the downstream reader YTHDF3 offers a highly localized therapeutic window, particularly in halting breast cancer brain metastasis and colon cancer progression.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (YTH Domain Inhibitors) | Accent Therapeutics, Storm Therapeutics | Solid Tumors, Breast Cancer Brain Metastasis | Selectivity Assay (Need high-purity YTHDF1, YTHDF2, and YTHDF3 proteins for FP/SPR screening) |
| PROTAC / Degraders | Academic & Biotech Consortia | Refractory Cancers, Immunotherapy Resistance | Target Degradation Validation (Need Lentivirus for stable reporter cell line construction) |
| RNA Therapeutics / siRNA | Epitranscriptomic Biotechs | Viral Infections, Triple-Negative Breast Cancer (TNBC) | Knockdown Efficiency & Specificity (Need validated siRNA and RT-qPCR control reagents) |